SCIENCE

Artificial General Health Intelligence

Bioentropy is at the forefront of pioneering Artificial General Health Intelligence (AGHI), harmonizing the collective wisdom of life and health sciences for humanity’s vast betterment. We are dedicated to the development of the future AGHI ecosystem, spanning smart device applications to an open-source foundational model community, which is promised to democratize premium personalized preventive healthcare. We are determined to fast-track breakthroughs in biomedical sciences and transform the biotech and biopharma industries, all in service of advancing human health and wellness.

Transforming life sciences, medicine and healthcare

Bioentropy’s AGHI initiative is forging an AGHI foundation model that melds life and health sciences with the physical and chemical disciplines. This model is primed for training with multi-scale multimodal data from biomolecules to human anatomy, aiming to attain a holistic comprehension of human biology, health, and disease. This AGI-based approach surpasses traditional scientific and healthcare boundaries, leveraging finely selected preclinical and clinical study data. The AGHI foundation model can fuel next-generation digital healthcare, life science discovery, biotechnology innovation and help to solve problems in biopharma and drug discovery that existing AI technology has failed to address. AGHI’s prowess in accelerating drug discovery is set to redefine the biopharma landscape, offering accurate prediction of viable drug targets, modeling of drug efficacy and facilitating virtual clinical trials, thus realizing the concept of personalized medicine.

Accelerating personalized drug discovery for neurodegenerative disease and beyond

The ultimate goal of Bioentropy task force is to democratize personalized healthcare and medicine. Bioentropy is committed to harnessing the synergy between the AGHI technology and advances of human immunology, neurobiology, and oncology, driving innovation in therapeutic target discovery and molecular design. Our strategy focuses on reprogramming human immunity and the protein-degradation machinery, forming a comprehensive AGHI-driven drug discovery platform. This platform propels the development of unconventional drug pipeline aimed at significant unmet medical needs. Recognizing disorders in innate immunity as key contributors to neurodegenerative disease pathogenesis, we are targeting aberrant inflammatory pathways in the brain’s microglia using cutting-edge AGHI. This approach holds the promise of novel treatments for neurodegenerative diseases and neuroinflammation.